Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403XQ | ISIN: US9186403013 | Ticker-Symbol:
NASDAQ
17.12.24 | 21:59
1,410 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VACCINEX INC Chart 1 Jahr
5-Tage-Chart
VACCINEX INC 5-Tage-Chart

Aktuelle News zur VACCINEX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Vaccinex, Inc.: Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting1
13.05.AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets272AbTherx and Single Cell Technology incorporate ActivMAb® Technology into Atlas Mouse and AbTheneum antibody discovery platforms MOUNTAIN VIEW, CA / ACCESS Newswire / May 13, 2025 / AbTherx, Inc., a...
► Artikel lesen
21.04.Vaccinex berichtet: Pepinemab verstärkt Immunantwort bei Krebserkrankungen3
21.04.Vaccinex reports pepinemab boosts immune response in cancer1
21.04.Vaccinex, Inc.: Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)1
15.04.VACCINEX, INC. - 10-K, Annual Report2
01.04.VACCINEX, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT4052
VACCINEX Aktie jetzt für 0€ handeln
27.03.VACCINEX, INC. - 15-12G, Securities registration termination2
19.03.VACCINEX, INC. - 8-K, Current Report1
17.03.VACCINEX, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities2
10.03.Vaccinex plans Nasdaq exit as Alzheimer market pressure grows3
07.03.Vaccinex plans to delist common stock from Nasdaq1
07.03.Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market189ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
► Artikel lesen
07.03.VACCINEX, INC. - 8-K, Current Report-
17.12.24Vaccinex, Inc.: Vaccinex Announces Receipt of Delisting Notification from Nasdaq170ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating...
► Artikel lesen
18.11.24Vaccinex, Inc.: Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update212Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage...
► Artikel lesen
05.11.24Vaccinex, Inc.: Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting206ROCHESTER, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
► Artikel lesen
14.08.24Vaccinex, Inc.: Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership186ROCHESTER, N.Y., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vaccinex (Nasdaq: VCNX) today provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's...
► Artikel lesen
31.07.24Vaccinex, Inc.: Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer's Disease246Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1